GlassScriptPhysician profile
Tehmina Naveed
NPI 1891873691
$7,538.74
in general payments reported to CMS, 2019-2025
24 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 88% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $502 · 2021: $638 · 2022: $752 · 2023: $1,217 · 2024: $1,253 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,591.09 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,273.57 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,100.10 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $855.25 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $522.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $417.12 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $256.73 | 2019-2021 | |
| Axsome Therapeutics, INC. | $243.39 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $226.22 | 2019 | |
| Indivior INC. | $213.69 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $149.80 | 2019-2023 | |
| Braeburn INC. | $125.00 | 2025 | Brixadi |
| Dexcom, INC. | $116.77 | 2023 | Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $110.79 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Amarin Pharma, INC. | $65.01 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $53.54 | 2019-2024 | Zubsolv |
| Exact Sciences Corporation | $45.30 | 2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $40.00 | 2020-2021 | |
| Abbvie INC. | $34.68 | 2021-2024 | |
| Horizon Therapeutics Plc | $34.42 | 2020-2021 | |
| Pfizer INC. | $20.20 | 2025 | |
| Clarus Therapeutics INC. | $15.15 | 2021 | |
| Eisai INC. | $14.40 | 2022 | |
| Astellas Pharma US INC | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tehmina Naveed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.